Related references
Note: Only part of the references are listed.Designing A Pathogen-Focused Study To Address The High Unmet Medical Need Represented By Carbapenem-Resistant Gram-Negative Pathogens - The International, Multicenter, Randomized, Open-Label, Phase 3 CREDIBLE-CR Study
Matteo Bassetti et al.
INFECTION AND DRUG RESISTANCE (2019)
Cefiderocol: a novel siderophore cephalosporin
Justin J. Choi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
Cefiderocol in context
Angela Huttner
LANCET INFECTIOUS DISEASES (2018)
Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options
Yoav Golan
BMC INFECTIOUS DISEASES (2015)
Share Paper
